Other Events ·
Capricor Therapeutics, Inc. announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee is…
CAPRCapricor Therapeutics, Inc.
Capricor Therapeutics, Inc. announced that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee is scheduled to convene on July 29, 2026, to discuss the company's Biologics License Application (BLA) for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD). The company's BLA remains on track for a PDUFA action date of August 22, 2026. Capricor Therapeutics, Inc. is a biotechnology company focused on developing cell and gene therapies for neuromuscular and neuromuscular-related diseases.